Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully passed the review for listing on the Sci-Tech Innovation Board, moving closer to its IPO after overcoming various challenges, including the expiration of financial documents [1] Fundraising and Financials - The company plans to raise approximately 2.4 billion yuan through the issuance of nearly 90 million shares, significantly lower than the previously planned 3.5 billion yuan [2][4] - The funds will be allocated to three main projects: 1.655 billion yuan for the construction of a recombinant human albumin industrialization base, over 600 million yuan for new drug research and development, and 100 million yuan for working capital [2][3] - The total investment for the recombinant human albumin industrialization base project is 1.909 billion yuan, with an expected annual production capacity of 120 tons of OsrHSA raw liquid [3] Revenue and Business Performance - The company has reported continuous losses over the past three years, with revenues of 13.4 million yuan in 2022, 24.3 million yuan in 2023, and an estimated 25.2 million yuan in 2024, while net profits were -122 million yuan, -187 million yuan, and -151 million yuan respectively [8][10] - The main source of revenue comes from pharmaceutical excipients and research reagents, with a small portion from beauty products, which accounted for less than 5% of total revenue [5][10] Legal Issues - The company is involved in a patent infringement lawsuit initiated by Ventria Bioscience, which claims that Heyuan's products infringe on its patents. The case has been ongoing since 2020, with a recent counter-suit filed by Heyuan against Ventria [12][13]

根据上交所公告，武汉禾元生物科技股份有限公司（简称"禾元生物"）将于7月1日接受科创板上市委员会 审议。作为科创板第五套上市标准重启后的首家上会企业，禾元生物凭借"稻米造血"这一创新技术，致力 于突破关键生物制品供应瓶颈，实现重组人白蛋白的战略自主可控，为中国乃至全球创新药行业开辟了一 条绿色、高效、可持续的生产新路径，精准呼应了科创板支持"硬科技"、鼓励突破性生物医药创新的政策 导向，为更多创新药企利用资本市场实现跨越式发展提供了示范路径。 用稻米"种"出救命药，成就生物医药创新典范 人血清白蛋白 是血浆中的主要蛋白成分，俗称"黄金救命药"，被广泛应用于治疗因失血、烧伤、烫伤、外 科手术引起的循环衰竭、脑损伤等引起的脑水肿、以及肝硬化、肾病综合征等导致的低白蛋白血症等，已 成为国内临床上使用最广泛的血制品，长期占据院内药品销售额排行榜第一名。 根据弗若沙利文数据，2023年中国人血白蛋白药用市场规模达到361亿元，预计2030年市场规模达到570亿 元人民币。然而，国内60%以上的供应依赖进口，血浆采集量仅能满足不到40%的需求。 瞄准这一市场蓝海及行业痛点，禾元生物开辟了颠覆性的技术路径—— 通过水稻胚乳 ...